Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Oncology Hopes Hit By CHMP Ninlaro Rejection; Appeal Planned

Executive Summary

An EMA advisory committee has set back Takeda Pharmaceutical Co. Ltd.’s oncology plans by rejecting Ninlaro as a treatment for multiple myeloma in the region, saying supporting data was inadequate for its backing but the Japanese company aims to appeal the decision.

You may also be interested in...



Takeda's Ninlaro Back In European Myeloma Race After CHMP Turnaround

A CHMP about turn on Takeda's Ninlaro (ixazomib) for multiple myeloma means the Japanese firm is back on track to compensate for lost revenues from the impending patent expiry of key product Velcade. However, the Japanese firm will have a tough time ensuring Ninlaro is not overshadowed by rivals.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval

Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.

Topics

Related Companies

UsernamePublicRestriction

Register

SC065296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel